Modification of hepatic iron metabolism induced by pravastatin during obstructive cholestasis in rats

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F11%3A10099490" target="_blank" >RIV/00216208:11150/11:10099490 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11160/11:10099490

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S0024320511004243" target="_blank" >http://www.sciencedirect.com/science/article/pii/S0024320511004243</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.lfs.2011.08.014" target="_blank" >10.1016/j.lfs.2011.08.014</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Modification of hepatic iron metabolism induced by pravastatin during obstructive cholestasis in rats

Popis výsledku v původním jazyce

The aim of the study was to evaluate iron biochemistry and contributing liver mechanisms during obstructive cholestasis and pravastatin treatment in rats. A rat model of cholestasis induced by bile duct ligation (BDL) was used for the study. The administration of pravastatin to BDL animals attenuated proliferation changes in liver parenchyma, prevented HO-1 induction, restored hepatic mRNA hepcidin expression to control levels and induced the mRNA expression of ferritin, transferrin receptors (TfR1/2) and divalent metal transporter-1. This was accompanied by an increased content of intrahepatic iron when compared to the BDL animals, and a reduction of hyperbilirubinemia. In conclusion, cholestasis-induced increase in plasma and decrease in hepatic ironlevels were associated with up-regulation of liver HO-1 and ferroportin 1. Pravastatin alleviated cholestatic liver impairment and raised liver iron content by modulation of heme catabolism and an increase of hepatic iron uptake and stor

Název v anglickém jazyce

Modification of hepatic iron metabolism induced by pravastatin during obstructive cholestasis in rats

Popis výsledku anglicky

The aim of the study was to evaluate iron biochemistry and contributing liver mechanisms during obstructive cholestasis and pravastatin treatment in rats. A rat model of cholestasis induced by bile duct ligation (BDL) was used for the study. The administration of pravastatin to BDL animals attenuated proliferation changes in liver parenchyma, prevented HO-1 induction, restored hepatic mRNA hepcidin expression to control levels and induced the mRNA expression of ferritin, transferrin receptors (TfR1/2) and divalent metal transporter-1. This was accompanied by an increased content of intrahepatic iron when compared to the BDL animals, and a reduction of hyperbilirubinemia. In conclusion, cholestasis-induced increase in plasma and decrease in hepatic ironlevels were associated with up-regulation of liver HO-1 and ferroportin 1. Pravastatin alleviated cholestatic liver impairment and raised liver iron content by modulation of heme catabolism and an increase of hepatic iron uptake and stor

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Life Sciences

ISSN

0024-3205

e-ISSN

—

Svazek periodika

89

Číslo periodika v rámci svazku

19

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

717-724

Kód UT WoS článku

000296311800007

EID výsledku v databázi Scopus

—